Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.
about
Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapyBalance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLCPeroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transitionThe investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imagingMinireview: Familiar Faces in Unfamiliar Places: The Emerging Role of Nuclear Receptors in Lung CancerType 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy.Targeting the eicosanoid pathway in non-small-cell lung cancer.Inhibition of cancer cell proliferation by PPARγ is mediated by a metabolic switch that increases reactive oxygen species levelsObesity and cancer--mechanisms underlying tumour progression and recurrencePPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcomaAnticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancerPeroxisome proliferator-activated receptors and cancer: challenges and opportunitiesPPARγ induces growth inhibition and apoptosis through upregulation of insulin-like growth factor-binding protein-3 in gastric cancer cells.Identification of urine protein biomarkers with the potential for early detection of lung cancer.Loss of PTEN Facilitates Rosiglitazone-Mediated Enhancement of Platinum(IV) Complex LA-12-Induced Apoptosis in Colon Cancer Cells.Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality.Cell death signaling and anticancer therapyEmerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases.The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination.Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours.PPARgamma activation induces autophagy in breast cancer cells.KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines.Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma.Molecular cross-regulation between PPAR-γ and other signaling pathways: implications for lung cancer therapy.PPAR gamma, bioactive lipids, and cancer progression.MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells.Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs.Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy.TGFβ can stimulate the p(38)/β-catenin/PPARγ signaling pathway to promote the EMT, invasion and migration of non-small cell lung cancer (H460 cells).
P2860
Q27015257-94DFFBE9-AE25-47CB-85BF-3F36D3385FABQ28478252-4429D5F0-C388-476E-9DD7-780039F07BFFQ30498249-B36D1643-3676-454C-8102-C44AD7A1B047Q33540291-2FEE44EE-0726-48BE-B278-65EE239E0B47Q33631471-0B536A57-AA60-4EB0-AD1E-10AACC0DB2E8Q33756414-6B81CA21-ED0D-4461-B7EE-587BDCA10602Q33936807-CD375BBF-3DAF-44B3-A3D0-1BB19BD6A1FAQ34315365-2073164E-EFEB-48B7-910A-463E44B295D8Q34425077-DD3B17AE-224B-4788-BAE6-3846F848F957Q34635550-E6966C50-6F2B-4E8E-AF4F-E90264F443ACQ34878637-74D9C33C-00F9-4195-B00D-5D3BDDF84539Q35210023-C5E01AA2-E562-4F3E-B227-9768BC0308D6Q35240559-1BA2C8D9-2B35-4497-AA06-F5E9E6232F99Q35809192-47CA7977-BA31-4BE2-A886-82D754424E44Q35817322-127CCF5A-36BC-4469-A055-D51A476FFD52Q35817986-30B12A63-7B3E-42FA-9955-A5E3697CAED8Q35972102-A25DC29A-B221-44C1-BB38-42856D4B461DQ36063833-6CAC0A17-59DF-4426-80FB-C5EE5D50B8CDQ36090448-C4B5E5B6-B72E-442C-82D6-1D515AD2FD40Q37188588-39E9EAFF-8E2E-4210-A945-88DCF0CE2638Q37366778-CC36F1E0-B52A-41E7-AE67-C4BC74FF5886Q37468620-B316B842-663D-43B5-BC39-F5B30F1AB01AQ37734011-EA5A9D6F-42B0-4BF1-AE03-4902050DE725Q37847515-BD9F55FA-C6DF-4905-A785-55F958AE6AE1Q37971590-D550338F-EBBC-43D2-8356-CD137A087B40Q38810052-124F2460-2623-4600-B46F-5ED69CA9EAB9Q44580484-380D87BF-6BFC-4A20-AC63-707D77D9033BQ47217961-067AA83F-24FB-416C-BFAD-294ABBF0906AQ48577765-0755E1DC-A30E-4DA7-A80B-35A019824987
P2860
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Regression of drug-resistant l ...... rosiglitazone and carboplatin.
@en
Regression of drug-resistant l ...... rosiglitazone and carboplatin.
@nl
type
label
Regression of drug-resistant l ...... rosiglitazone and carboplatin.
@en
Regression of drug-resistant l ...... rosiglitazone and carboplatin.
@nl
prefLabel
Regression of drug-resistant l ...... rosiglitazone and carboplatin.
@en
Regression of drug-resistant l ...... rosiglitazone and carboplatin.
@nl
P2093
P2860
P50
P1476
Regression of drug-resistant l ...... rosiglitazone and carboplatin
@en
P2093
Bruce M Spiegelman
Elnaz Naseri
Geoffrey D Girnun
George Demetri
Jeremy Force
Jessica Silvaggi
Kate McNamara
Liang Chen
Lucian R Chirieac
P2860
P304
P356
10.1158/1078-0432.CCR-08-1128
P407
P577
2008-10-01T00:00:00Z